Preclinical Explorative Assessment of Celecoxib-Based Biocompatible Lipidic Nanocarriers for the Management of CFA-Induced Rheumatoid Arthritis in Wistar Rats
- 165 Downloads
Celecoxib (CXB), a COX-2 inhibitor, is primarily indicated for long-term treatment of rheumatoid arthritis (RA). The effective therapeutic efficacy of CXB on RA via oral administration shows adverse systemic complications, and therefore, local application of CXB has been recommended. The aim of the present study was to develop and characterize solid lipid nanoparticles (SLNs) with enhanced skin permeation potential of CXB. The particle size, polydispersity index (PDI), and percentage drug entrapment (PDE) of the developed SLNs (CXB-SLNs) were found to be 240 nm, < 0.3, and ~ 86% respectively. The developed SLNs exhibited sustained release up to 70% at the end of 48 h. Drug permeation was found to be 45% for SLN gel and 31% for conventional gel. The dermatokinetic studies also confirmed enhanced permeation of CXB in the epidermis and dermis and revealed superiority of the developed SLN gel vis-à-vis the conventional gel. Further, in the CFA-induced arthritis rat model, % arthritis index (AI) of the CXB-SLN gel formulation was found to be very less (18.54%) as compared to untreated (187.34%) and conventional gel-treated (91.61%) animals. In conclusion, the current study can provide a suitable alternative for the development of an effective topical formulation of CXB in lipid nanocarriers.
KEY WORDScelecoxib lipid nanocarriers skin permeation rheumatoid arthritis
The first author received an SRF fellowship from the Indian Council of Medical Research (ICMR), New Delhi (ref no. 45/31/2013-Nan/BMS).
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
- 5.Wong R, Davis A, Badley E, Grewal R, Mohammed M. Prevalence of arthritis and rheumatic diseases around the world: a growing burden and implications for health care needs. Model. Care Arthritis, Bone Jt. Dis. 2010;1–110. Available from: papers://6d7233c7-0c7f-43d7-b776-a2bbe7398ece/Paper/p2171.Google Scholar
- 6.Garner SE, Fidan D, Frankish RR, Judd M, Shea B, Towheed T, et al. Celecoxib for rheumatoid Arthritis. Cochrane Database Syst Rev. 2017;Google Scholar
- 7.Fujimori S, Hanada R, Hayashida M, Sakurai T, Ikushima I, Sakamoto C. Celecoxib monotherapy maintained small intestinal mucosa better compared with loxoprofen plus lansoprazole treatment a double-blind, randomized, controlled trial. J Clin Gastroenterol. 2016;50:218–26.CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Gisvold W and. Organic medicinal and pharmaceutical chemistry. 12th ed. Lippincott Williams and Wilkins; 2011.Google Scholar
- 11.Walters KA, K.R. B. Dermatological formulation and transdermal systems. Dermatol Transdermal Formul. 2002;Google Scholar
- 12.Barry BW. Transdermal drug delivery. Pharm Des Manuf Med. 2007:409–533.Google Scholar
- 22.Schäfer-Korting M, Mehnert W, Korting HC. Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv Drug Deliv Rev. 2007. p. 427–43.Google Scholar
- 27.Garg NK, Sharma G, Singh B, Nirbhavane P, Tyagi RK, Shukla R, et al. Quality by Design (QbD)-enabled development of aceclofenac loaded-nano structured lipid carriers (NLCs): an improved dermatokinetic profile for inflammatory + (s). Int J Pharm. 2017;517:413–31.CrossRefPubMedPubMedCentralGoogle Scholar
- 34.Ekambaram S, Perumal SS, Subramanian V. Evaluation of antiarthritic activity of Strychnos potatorum Linn seeds in Freund’s adjuvant induced arthritic rat model. BMC Complement Altern Med. 2010;10Google Scholar
- 36.Kaur A, Bhoop BS, Chhibber S, Sharma G, Gondil VS, Katare OP. Supramolecular nano-engineered lipidic carriers based on diflunisal-phospholipid complex for transdermal delivery: QbD based optimization, characterization and preclinical investigations for management of rheumatoid arthritis. Int J Pharm. 2017;533:206–24.CrossRefGoogle Scholar
- 37.Dubey V, Mishra D, Dutta T, Nahar M, Saraf DK, Jain NK. Dermal and transdermal delivery of an anti-psoriatic agent via ethanolic liposomes. J. Control. Release. 2007;Google Scholar
- 44.Sharma G, Kamboj S, Thakur K, Negi P, Raza K, Katare OP. Delivery of thermoresponsive-tailored mixed micellar nanogel of lidocaine and prilocaine with improved dermatokinetic profile and therapeutic efficacy in topical anaesthesia. AAPS PharmSciTech. 2017;18:790–802.CrossRefPubMedPubMedCentralGoogle Scholar